AFP3h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain Medicines
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
FDA green lights new painkiller
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
News Highlights: Top Company News of the Day - Friday at 1 AM ET
The company has heavily advertised AI features since the latest iPhones were released in September. Revenue rose 10% from a year ago to $9.5 billion. The shift occurs after many brands cut their ...
precisionmedicineonline3h
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.